At present two major problems of modern-medicine are management of drug refractory sepsis and cancers. As an alternative, colloidal nanomedicines have proved highly promising for cytotoxicity on any microbes or cancers by all theory-testing, but are kept in abeyance for clinical applications due to unacceptable toxicity risk on some host cells and most of environmental microbes. Filling many research-gaps, highprecision self-serum capped silver nanoparticles have brought new ray of hope, being small but wide cluster range colloidal particles with compatible range of surface charge for suspending cellular particles in blood and identical molecular signs on surface-cap. These can more precisely encounter high anionic invader microbes and cancer cells by high attractive charge affinity, particularly on narrow contact-points of iondiffusible tuneable caps, according to rule of physics. High anionic nanoparticles in blood, take time to transform into low anionic serum compatibility after corona-like protein deposition on surface. So, they repel target cells but can encounter many host cells on the way, including RBC and endothelial cells, while larger nanoparticles are restricted to enter into bacteria, though clathrin-mediated endocytosis is possible in eukaryotic cells. For molecular-sign differences, non-serum capped nanoparticles may endocytose into many hostcells and microbes. As personalised nanomedicine has no chance of massive spillage, are safe for environment. In this review, scopes and limitations of such novel class nanoparticles have been discussed from therapeutic point of view.
Maiti Prasanta Kumar* (Fri,) studied this question.